Health Insurance Providers Stocks Q4 Overview: Comparing Cigna (NYSE:CI)

Health Insurance Providers: Q4 Earnings Review

With the fourth quarter earnings season wrapping up, it's a good opportunity to assess which health insurance companies stood out, both positively and negatively, including Cigna (NYSE:CI) and its industry counterparts.

Health insurers benefit from steady income through upfront premium collections, but their profitability hinges on precise risk evaluation and effective management of healthcare expenses. The sector is also highly influenced by regulatory shifts and broader economic trends, such as changes in employment rates. Looking ahead, the industry is set to benefit from demographic shifts like an aging population, rising interest in personalized healthcare, and the use of advanced data analytics for cost control. However, ongoing regulatory oversight, possible government reforms such as expanded public healthcare, and rising medical costs could introduce uncertainty to profit margins. Investors are also debating the long-term effects of artificial intelligence—whether it will enhance processes like underwriting and fraud detection, or potentially introduce ethical challenges by reinforcing biases in healthcare delivery.

Industry Performance Overview

Among the 12 health insurance stocks monitored, the group experienced a slower fourth quarter. Collectively, their revenues surpassed analyst forecasts by 0.8%, while guidance for the next quarter was generally in line with expectations.

Despite these results, share prices have struggled, with the group seeing an average decline of 5.4% since their latest earnings announcements.

Cigna (NYSE:CI)

Tracing its origins back to 1792, The Cigna Group (NYSE:CI) serves millions worldwide through its Evernorth Health Services and Cigna Healthcare divisions, offering a range of services including pharmacy benefits, specialty care, and medical insurance plans.

For the quarter, Cigna reported $72.5 billion in revenue, marking a 10.4% increase year over year and surpassing analyst projections by 3.8%. While the company outperformed on revenue, its full-year guidance came in slightly below Wall Street expectations, making for a mixed quarter overall.

David M. Cordani, Cigna’s chairman and CEO, commented: “In 2025, we expanded access and support, lowered costs, and improved transparency for our customers and patients.”

Cigna Total Revenue

Investors appeared to have anticipated these results, as Cigna’s stock price has remained steady since the report and is currently trading at $272.18.

Top Q4 Performer: Clover Health (NASDAQ:CLOV)

Established in 2014 with a mission to enhance senior healthcare through technology, Clover Health (NASDAQ:CLOV) specializes in Medicare Advantage plans, emphasizing affordability and leveraging its proprietary Clover Assistant software to support physicians in patient care management.

In the fourth quarter, Clover Health generated $487.7 million in revenue, a 44.7% year-over-year increase and 4.4% above analyst estimates. The company delivered strong results, beating revenue expectations and matching earnings per share forecasts.

Clover Health Total Revenue

Clover Health achieved the largest revenue beat and fastest growth among its peers, adding 4,577 new members for a total of 113,803. Despite these achievements, the market reacted negatively, with the stock dropping 7.3% since the earnings release and currently trading at $1.99.

Q4’s Weakest: Molina Healthcare (NYSE:MOH)

Founded in 1980 to serve underserved populations in Southern California, Molina Healthcare (NYSE:MOH) now delivers managed healthcare services to low-income individuals through Medicaid, Medicare, and Marketplace plans across 21 states.

Molina Healthcare reported $11.38 billion in revenue for the quarter, up 8.3% year over year and 3.7% above analyst expectations. However, the company’s full-year revenue and earnings guidance fell well short of forecasts, resulting in a weaker quarter overall.

As a result, Molina’s stock has declined 19.1% since the earnings report and is currently priced at $143.14.

CVS Health (NYSE:CVS)

With a network of over 9,000 retail pharmacies nationwide, CVS Health (NYSE:CVS) acts as a community health hub, offering pharmacy services, pharmacy benefit management, and health insurance through its Aetna division.

CVS Health posted $105.7 billion in revenue for the quarter, an 8.2% increase year over year and 2% above analyst expectations. The company had a solid quarter, exceeding revenue forecasts but narrowly missing full-year earnings per share guidance.

Following the earnings announcement, CVS shares have risen 2.7% and are now trading at $77.84.

Oscar Health (NYSE:OSCR)

Oscar Health (NYSE:OSCR), launched in 2012, aims to demystify the complex U.S. healthcare system. The company focuses on technology-driven health insurance solutions for individuals and small businesses, delivered through its cloud-based platform.

Oscar Health reported $2.81 billion in revenue for the quarter, a 17.3% year-over-year increase but 10.2% below analyst projections. While the company raised its full-year operating income guidance above expectations, it significantly missed revenue estimates, resulting in a mixed performance.

Oscar Health provided the largest upward adjustment to full-year guidance among its peers but also had the weakest performance relative to analyst expectations. The stock has climbed 9.1% since the earnings release and is currently valued at $13.81.

Looking for Strong Growth Stocks?

If you’re interested in companies with robust fundamentals, explore our Top 5 Growth Stocks and consider adding them to your watchlist. These businesses are well-positioned to thrive regardless of political or economic shifts.

The StockStory analyst team, comprised of experienced professional investors, leverages quantitative research and automation to deliver timely, high-quality market insights.